5.3 Oncology, Hematology & Diagnostic Radiology

5.3 Oncology, Hematology & Diagnostic Radiology

Principles of Oncology & Cancer Staging

Oncology is the medical subspecialty devoted to the study, diagnosis, treatment, and prevention of cancer. Cancer arises from genetic mutations that cause uncontrolled cellular proliferation, leading to the formation of a neoplasm (tumor). Neoplasms are classified as benign (non-cancerous, localized, non-invasive) or malignant (cancerous, invasive, capable of invading adjacent tissues and distant organs).

To describe the anatomical extent of a malignant tumor and formulate prognosis and treatment plans, clinicians utilize the standardized TNM Staging System developed by the American Joint Committee on Cancer (AJCC):

Overall Stage Grouping: TNM values are combined into overall Roman numeral stages:

• Stage 0: Carcinoma in situ (non-invasive).
• Stage I to III: Localized to locally advanced cancer, with increasing tumor size and lymph node spread.
• Stage IV: Advanced metastatic cancer that has spread to distant organs.

Histologic Grading: Separate from staging, tumor grade (G1 to G4) describes how closely cancer cells resemble normal tissue under microscopic evaluation. Well-differentiated cells (G1) grow slowly, whereas undifferentiated/anaplastic cells (G4) are highly aggressive.

Diagnostic Biopsies & Cancer Treatment Modalities

A definitive cancer diagnosis mandates microscopic pathological examination of tissue obtained through a biopsy:

• Fine Needle Aspiration (FNA): A thin-gauge needle extracts fluid or small cellular clusters from suspicious masses (e.g., thyroid nodules, breast lesions).
• Core Needle Biopsy: A larger hollow needle extracts intact tissue cores, preserving cellular architecture.
• Excisional vs. Incisional Biopsy: Excisional biopsy removes an entire lesion; incisional biopsy removes a representative portion of a large mass.
• Liquid Biopsy: Analysis of circulating tumor DNA (ctDNA) or circulating tumor cells from peripheral blood samples.

Multimodal Cancer Therapeutics:

1. Surgical Resection: Primary removal of solid tumors and surrounding clear margins, often accompanied by sentinel lymph node biopsy.
2. Chemotherapy: Systemic administration of cytotoxic drugs that disrupt cell division. Can be neoadjuvant (given before surgery to shrink tumors) or adjuvant (given after surgery to eradicate microscopic residual disease). Common adverse effects include neutropenia (suppressed neutrophils causing severe infection risk), thrombocytopenia (bleeding risk), alopecia (hair loss), mucositis (painful mouth sores), and chemotherapy-induced peripheral neuropathy.
3. Radiation Therapy: High-energy ionizing radiation (X-rays, gamma rays) directed locally to destroy cancer cell DNA. Delivered via External Beam Radiation Therapy (EBRT) or Brachytherapy (internal placement of radioactive seeds).
4. Immunotherapy & Targeted Therapy: Monoclonal antibodies, immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), and small-molecule tyrosine kinase inhibitors that target specific molecular mutations or boost the patient's immune response against malignant cells.

Clinical Hematology & Blood Disorders

Hematology is the study of blood, blood-forming organs, and hematologic diseases. The fundamental lab test encountered by interpreters is the Complete Blood Count (CBC) with Differential:

Major Hematologic Conditions:

• Leukemias: Malignancies of blood-forming bone marrow cells (Acute Lymphoblastic Leukemia - ALL, Acute Myeloid Leukemia - AML, Chronic Lymphocytic Leukemia - CLL, Chronic Myeloid Leukemia - CML).
• Lymphomas: Cancers originating in the lymphatic system, divided into Hodgkin Lymphoma (marked by Reed-Sternberg cells) and Non-Hodgkin Lymphoma (NHL).
• Coagulopathies & Thrombosis: Hemophilia (hereditary clotting factor deficiency), Deep Vein Thrombosis (DVT), and Pulmonary Embolism (PE).

Diagnostic Radiology Modalities

Diagnostic radiology utilizes radiant energy to visualize internal body structures for diagnosis and procedural guidance:

• Plain Radiography (X-ray): Uses ionizing radiation to image dense structures like bones and lungs (fractures, pneumonia).
• Computed Tomography (CT / CAT Scan): Cross-sectional X-ray imaging processed by computer algorithms to generate 3D views of soft tissues, blood vessels, and organs.
• Magnetic Resonance Imaging (MRI): Uses powerful magnetic fields (1.5T to 3.0T) and radiofrequency pulses—without ionizing radiation—to produce high-resolution images of soft tissues, brain, spinal cord, and musculoskeletal joints.
• Positron Emission Tomography (PET Scan): Nuclear medicine technique where a radiotracer (fluorodeoxyglucose - FDG) is injected to measure tissue metabolic activity. Malignant tumors absorb high levels of FDG, making PET scans ideal for detecting metastases.
• Ultrasound (Sonography): High-frequency sound waves producing real-time structural and vascular (Doppler) images without radiation.

Contrast Media Safety & Patient Screening Protocols

Radiological studies frequently require contrast agents to highlight vascular structures and tissue borders:

• Iodinated Contrast (used in CT & Angiography): Injected intravenously. Risk of adverse reactions ranging from mild urticaria (hives) to severe anaphylaxis.
• Contrast-Induced Nephropathy (CIN): Iodinated contrast can impair renal function. Providers must evaluate Blood Urea Nitrogen (BUN), Serum Creatinine, and Estimated Glomerular Filtration Rate (eGFR) prior to injection.
• Gadolinium-Based Contrast (used in MRI): Poses risk of Nephrogenic Systemic Fibrosis (NSF) in patients with severe renal failure.
• MRI Safety Screening: Strong magnetic fields turn ferromagnetic objects into dangerous projectiles. Interpreters must meticulously translate pre-MRI screening questionnaires verifying the absence of pacemakers, metallic vascular clips, cochlear implants, or metallic shrapnel.

Clinical Scenarios & Interpreter Strategies

• Scenario 1: Communicating a Stage IV Lung Cancer Diagnosis: An oncologist informs a patient that their non-small cell lung cancer has metastasized to the bone (Stage IV). The interpreter must convey the grave prognosis accurately, maintaining a neutral, respectful tone while preserving the exact medical details.
• Scenario 2: Pre-MRI Safety Screening for a Patient with Metal Remnants: An interpreter translates an safety checklist for an elderly patient scheduled for a brain MRI. When the patient mentions working as a welder, the interpreter relays this critical detail immediately, prompting the technologist to order orbital X-rays to rule out metallic eye fragments.
• Scenario 3: Explaining Neutropenic Precautions: An oncology nurse provides discharge instructions to a patient undergoing chemotherapy with severe neutropenia. The interpreter translates strict hygiene, temperature monitoring, and dietary restrictions clearly to prevent life-threatening sepsis.

Common Pitfalls & Exam Traps

• Radiation vs. Magnetic Field Trap: Remember that CT scans and X-rays use ionizing radiation, whereas MRIs use magnetic fields and radio waves (no radiation).
• Biopsy Types: Do not confuse FNA (cell aspiration via thin needle) with core needle biopsy (tissue cylinder extraction preserving architecture).
• Empathy vs. Medical Fidelity: In devastating oncological consultations, interpreters must refrain from offering personal comforting phrases ("Everything will be okay") or altering the doctor's words.